CSB 2.010 Note Section 961.14 (2) (ai), Stats., was renumbered to s. 961.14 (2) (nd) 3. by 2017 Wis. Act 60. CSB 2.010 HistoryHistory: EmR1710: emerg. cr., eff. 5-2-17; CR 17-040: cr. Register November 2017 No. 743, eff. 12-1-17; correction made under s. 35.17, Stats., Register November 2017 No. 743. CSB 2.010 NoteCSB 2.54 Addition of oral solutions containing dronabinol to schedule II. Section 961.16 (10), Stats., is created to read: CSB 2.010 Note961.16 (10) (a) Dronabinol [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)] in an oral solution in a drug product approved by the U.S. food and drug administration.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2017 No. 737, eff. 5-15-17; CR 18-055: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.010 NoteCSB 2.55 Addition of 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA to schedule I. Section 961.14 (4) (tb) 38., 39., 40., 41., and 42., Stats., is created to read: CSB 2.010 Note961.14 (4) (tb) 38. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-ADB.
CSB 2.010 Note39. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as 5F-AMB.
CSB 2.010 Note40. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as ADB-FUBINACA.
CSB 2.010 Note41. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate commonly known as MDMB-CHMICA.
CSB 2.010 Note42. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as MDMB-FUBINACA.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2017 No. 737, eff. 5-15-17; CR 17-088: cr. Register October 2018 No. 754, eff. 11-1-18. CSB 2.010 NoteCSB 2.56 Addition of 4-fluoroisobutyryl fentanyl to schedule I. Section 961.14 (2) (nd) 10t., Stats., is created to read: CSB 2.010 Note961.14 (2) (nd) 10t. 4-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2017 No. 738, eff. 6-12-17; CR 17-089: cr. Register October 2018 No. 754, eff. 11-1-18. CSB 2.010 NoteCSB 2.57 Scheduling of cyclopropyl fentanyl. Section 961.14 (2) (nd) 10d., Stats., is created to read: CSB 2.010 Note961.14 (2) (nd) 10d. Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);
CSB 2.010 HistoryHistory: EmR 1716: emerg. cr. eff. 9-8-17; CR 17-0785: cr. Register July 2018 No. 751, eff. 8-1-18; corrections made under s. 35.17, Stats., Register July 2018 No. 751. CSB 2.010 Note961.16 (2) (a) (intro) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2017 No. 743, eff. 11-20-17; CR 18-024: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.010 NoteCSB 2.59 Addition of ortho-fluorofentanyl to schedule I. Section 961.14 (2) (nd) 16m., Stats., is created to read: CSB 2.010 Note961.14 (2) (nd) 16m. Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-4-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-023: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.010 NoteCSB 2.60 Addition of FUB-AMB to schedule I. Section 961.14 (4) (tb) 43., Stats., is created to read: CSB 2.010 Note961.14 (4) (tb) 43. methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, commonly known as FUB-AMB, MMB-FUBINACA or AMB-FUBINACA.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2017 No. 744, eff. 12-11-17; correction made under s. 35.17, Stats., Register December 2017 No. 744; CR 18-022: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.010 NoteCSB 2.61 Addition of MT-45 to schedule I. Section 961.14 (2) (rk), Stats., is created to read: CSB 2.010 Note961.14 (2) (rk) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register January 2018 No. 745, eff. 1-22-18; correction made under s. 35.17, Stats., Register January 2018 No. 745; CR 18-069: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.010 NoteCSB 2.62 Addition of para-chloroisobutyryl fentanyl to schedule I. Section 961.14 (2) (nd) 16s., Stats., is created to read: CSB 2.010 Note961.14 (2) (nd) 16s. Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3-12-18; CR 18-070: cr. Register June 2019 No. 762, eff. 7-1-19. CSB 2.010 NoteCSB 2.63 Addition of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA to schedule I. Section 961.14 (4) (tb) 44., 45., 46., 47., and 48., Stats., are created to read: CSB 2.010 Note961.14 (4) (tb) 44. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, commonly known as NM2201.
CSB 2.010 Note45. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, commonly known as 5F-AB-PINACA.
CSB 2.010 Note46. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 4-CN-CUMYL-BUTINACA.
CSB 2.010 Note47. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-CHMICA.
CSB 2.010 Note48. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide, commonly known as 5F-CUMYL-P7AICA.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2018 No. 747, eff. 3-12-18; cr. Affirmative action order under s. 961.11 (4), Stats., Register August 2018 No. 752, eff. 8-13-18; correction made under s. 35.17, Stats., Register August 2018 No. 752; CR 19-010: cr. Register June 2020 No. 774, eff. 7-1-20; correction made under s. 35.17, Stats., Register June 2021 No. 786. CSB 2.010 NoteCSB 2.64 Addition of N-Ethylpentylone to schedule I. Section 961.14 (7) (L) 34., Stats., is created to read: CSB 2.010 Note961.14 (7) (L) 34. N-Ethylpentylone, commonly known as ephylone.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2018 No. 754, eff. 10-8-18; CR 19-011: cr. Register June 2020 No. 774, eff. 7-1-20. CSB 2.010 NoteCSB 2.65 Addition of approved cannabidiol drugs to schedule V. Section 961.22 (7), Stats., is created to read: CSB 2.010 Note961.22 (7) Approved cannabidiol drugs. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register October 2018 No. 754, eff. 10-15-18; CR 19-012: cr. Register June 2020 No. 774, eff. 7-1-20. CSB 2.010 NoteCSB 2.66 Addition of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 to schedule I. Section 961.14 (4) (tb), 49., 50., 51., 52., and 53., Stats., are created to read: CSB 2.010 Note961.14 (4) (tb) 49. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-EDMB-PINACA.
CSB 2.010 Note50. Methyl 2-(1-(5-fluoropentyl)-1-indole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PICA.
CSB 2.010 Note51. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, commonly known as FUB-AKB48, FUB-APINACA or AKB48 N-(4-FLUOROBENZYL).
CSB 2.010 Note52. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, commonly known as 5F-CUMYL-PINACA or SGT-25.
CSB 2.010 Note53. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone, commonly known as FUB-144.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2019 No. 759, eff. 3-11-19; CR 20-048: cr. Register June 2021 No. 786, eff. 7-1-21. CSB 2.010 NoteCSB 2.67 Addition of Brexanolone and Solriamfetol to schedule IV. Section 961.20 (2) (ap) and (2m) (g), Stats., are created to read: CSB 2.010 Note961.20 (2) (ap) Brexanolone;
CSB 2.010 Note(2m) (g) Solriamfetol.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2019 No. 763, eff. 7-22-19; CR 20-049: cr. Register June 2021 No. 786, eff. 7-1-21; correction in (2) (ap) made under s. 35.17, Stats., Register June 2021 No. 785. CSB 2.010 NoteCSB 2.68 Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP to schedule I. Section 961.14 (7) (L) 35. to 40., Stats., is created to read: CSB 2.010 Note961.14 (7) (L) 35. N-Ethylhexedrone.
CSB 2.010 Note36. Alpha-pyrrolidinohexanophenone, commonly known as a-PHP.
CSB 2.010 Note37. 4-methyl-alpha-ethylainopentiophenone, commonly known as 4-MEAP.
CSB 2.010 Note38. 4’-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.
CSB 2.010 Note39. Alpha-pyrrolidinoheptaphenone, commonly known as PV8.
CSB 2.010 Note40. 4’-chloro-alpha-pyrrolidinovalerophenone, commonly known as 4-chloro-a-PVP.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register August 2019 No. 764, eff. 8-19-19; CR 20-050: cr. Register June 2021 No. 786, eff. 7-1-21. CSB 2.010 NoteCSB 2.69 Addition of Noroxymorphone to schedule II. Section 961.16 (2) (a) 10m., Stats., is created to read: CSB 2.010 Note961.16 (2) (a) 10m. Noroxymorphone.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2019 No. 767, eff. 11-11-19; CR 20-051: cr. Register June 2021 No. 786, eff. 7-1-21. CSB 2.010 NoteCSB 2.70 Scheduling 4F-MDMB-BINACA and MMB-FUBICA. Section 961.14 (4) (tb) 38m. and 43m., Stats., are created to read: CSB 2.010 Note961.14 (4) (tb) 38m. Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA.
CSB 2.010 Note43m. Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-FUBICA or AMB-FUBICA.
CSB 2.010 HistoryHistory: EmR2017: emerg. cr., eff. 6-26-20; CR 20-022: cr. Register May 2021 No. 785, eff. 6-1-21. CSB 2.010 NoteCSB 2.71 Addition of lasmiditan to schedule V. Section 961.22 (8), Stats., is created to read: CSB 2.010 Note961.22 (8). Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide].
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 3-23-20; CR 20-058: cr. Register July 2021 No. 787, eff. 8-1-21. CSB 2.010 NoteCSB 2.72 Scheduling of isotonitazene and 1P-LSD. Section 961.14 (2) (pe) and (4) (jm), Stats., are created to read: CSB 2.010 Note961.14 (2) (pe) Isotonitazene;
CSB 2.010 Note961.14 (4) (jm) 1-propionyl-lysergic acid diethylamide, commonly known as 1P-LSD;
CSB 2.010 HistoryHistory: EmR2013: emerg. cr., eff. 6-5-20; CR 20-023: cr. Register May 2021 No. 785, eff. 6-1-21; correction made under s. 35.17, Stats., Register May 2021 No. 785. CSB 2.010 NoteCSB 2.73 Addition of cenobamate to schedule V. Section 961.22 (9), Stats., is created to read: CSB 2.010 Note961.22 (9) CENOBAMATE Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester)
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2020 No. 773, eff. 5-18-20; CR 20-075: cr. Register July 2021 No. 787, eff. 8-1-21. CSB 2.010 NoteCSB 2.74 Addition of Lemborexant to schedule IV. Section 961.20 (2) (eqm), Stats., is created to read: CSB 2.010 Note961.20 (2) (eqm) Lemborexant.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 5-18-20; CR 20-076: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787. CSB 2.010 NoteCSB 2.75 Exclusion of approved cannabidiol drugs from schedule I. (1) Section 961.14 (4) (t) 4., Stats., is created to read: CSB 2.010 Note961.14 (4) (t) 4. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.
CSB 2.010 Note(2) Section 961.22 (7) is repealed.
CSB 2.010 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register June 2020 No. 774, eff. 6-29-20; CR 20-077: cr. Register July 2021 No. 787, eff. 8-1-21.
